PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3986.96%
Growth of 3986.96% versus flat Biotechnology revenue. Walter Schloss would verify growth quality.
No Data
No Data available this quarter, please select a different quarter.
804.39%
Growth of 804.39% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
117.23%
Margin change of 117.23% versus flat Biotechnology margins. Walter Schloss would verify quality.
-19.33%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-34.65%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.37%
Operating expenses reduction while Biotechnology median is 0.27%. Seth Klarman would investigate advantages.
-24.37%
Total costs reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.46%
EBITDA change of 36.46% versus flat Biotechnology. Walter Schloss would verify quality.
98.45%
Margin change of 98.45% versus flat Biotechnology. Walter Schloss would verify quality.
35.83%
Income change of 35.83% versus flat Biotechnology. Walter Schloss would verify quality.
98.43%
Margin change of 98.43% versus flat Biotechnology. Walter Schloss would verify quality.
-7.89%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
35.97%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
98.43%
Margin change of 98.43% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
36.40%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
98.44%
Margin change of 98.44% versus flat Biotechnology. Walter Schloss would verify quality.
37.84%
EPS change of 37.84% versus flat Biotechnology. Walter Schloss would verify quality.
37.84%
Diluted EPS change of 37.84% versus flat Biotechnology. Walter Schloss would verify quality.
2.81%
Share count reduction below 50% of Biotechnology median of 0.58%. Jim Chanos would check for issues.
2.81%
Diluted share reduction below 50% of Biotechnology median of 0.45%. Jim Chanos would check for issues.